Opinion|Videos|January 23, 2026
Debate Topic 3: Benefits of Completing Lupatercept
Experts debate the optimal dose escalation strategy for Luspatercept in treating low-risk MDS, emphasizing patient-centric approaches and long-term outcomes.
Advertisement
Episodes in this series
Advertisement
Related to this article
Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.
Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.
Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.
Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC.
At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.
Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.
Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma
2
Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer
3
Why High-Risk Stage I NSCLC Needs a Post-Surgical Vaccine Option
4
Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer
5